Semarion Announces Early Adopter Programme for SemaCyte Microcarrier Platform

CAMBRIDGE, England--(BUSINESS WIRE)--Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced the opening of its Early Adopter Programme for its SemaCyte® Microcarrier Platform. The platform overcomes current limitations associated with adherent cell culture and assaying workflows by enabling small colonies of cells to be moved and frozen in their adherent state,